R Retreatment in 1st Relapsed DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00980304
Recruitment Status : Unknown
Verified September 2009 by Shanghai Jiao Tong University School of Medicine.
Recruitment status was:  Not yet recruiting
First Posted : September 21, 2009
Last Update Posted : September 21, 2009
Information provided by:
Shanghai Jiao Tong University School of Medicine

Brief Summary:

It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to receive 3 cycles of RICE as salvage therapy.

After treatment each patient should be followed up for 2 years.

Condition or disease Intervention/treatment Phase
Lymphomas Drug: Rituximab Phase 2

Study Type : Interventional  (Clinical Trial)
Official Title: A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo

Arm Intervention/treatment
Experimental: Rituximab in combination with ICE as salvage therapy Drug: Rituximab

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Relapsed DLBCL patients having received 6 - 8 cycles of RCHOP-like chemotherapy as 1st line induction treatment.
  2. Disease relapsed no earlier than 6 months after prior induction treatment.
  3. Confirmed CD20 positivity of the lymphoma at time of diagnosis (prior to induction therapy)
  4. ECOG performance status of 0, 1 or 2 at time of inclusion (see Appendix IV )
  5. Known IPI at time of diagnosis (prior to induction therapy)
  6. Age ≥18 years and <65 y
  7. Life expectancy of > 3 months
  8. Be willing and able to comply with the protocol for the duration of the study
  9. Agree to use effective contraception for the entire treatment period and during the 12 months thereafter
  10. Patient's written informed consent

Exclusion Criteria:

  1. More than one prior chemoimmunotherapy regimen.
  2. Histologies other than DLBCL according to the WHO/REAL classification
  3. History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin, surgically treated malignant melanoma or carcinoma in situ of the cervix within the last 5 years.
  4. Major surgery, other than diagnostic surgery, within the last 4 weeks.
  5. Evidence of CNS involvement patients
  6. Unacceptable hematologic status at baseline prior to study start below any of the values listed: WBC: <3 x 109/L; absolute neutrophil count (segmented + bands) <1.5 x 109/L; platelets: <100 x109/L
  7. Abnormal liver function tests prior to study start above any of the values listed: serum bilirubin >2 mg/dL (30 mmol/L); ALAT or ASAT >2.5 x upper limit of normal range; or Abnormal renal function (serum creatinine > 150 μmol/L ).
  8. HIV-positive patients.
  9. Contraindication to the investigational medication
  10. Active viral hepatitis, specifically HBV or HCV infection
  11. Serious underlying medical conditions, (e.g. ongoing infection, uncontrolled diabetes mellitus, severe cardiac dysfunction or angina, gastric ulcers, active autoimmune disease)
  12. Life expectancy < 3 months
  13. Treatment within a clinical trial within 30 days prior to trial entry
  14. Women who are breast feeding, are not using effective contraception, are pregnant
  15. Patients under tutelage

Responsible Party: Shen, Zhixiang / Professor, Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine Identifier: NCT00980304     History of Changes
Other Study ID Numbers: ML22515
First Posted: September 21, 2009    Key Record Dates
Last Update Posted: September 21, 2009
Last Verified: September 2009

Keywords provided by Shanghai Jiao Tong University School of Medicine:
Diffuse large B cell lymphomas

Additional relevant MeSH terms:
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents